Many drugs are available for schizophrenia, but insufficient efficacy and intolerable side effects leave an unmet need that biotech companies are still trying to fill. LB Pharmaceuticals is not ...
LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week ...
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major ...
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE)-- LB Pharmaceuticals Inc ("LB Pharmaceuticals” or the "Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results